Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States

Matthew S. Davids(Dana-Farber Cancer Institute), Michael Hallek(Integrated Oncology (United States)), Anuja Chatterjee(Dana-Farber Cancer Institute), Beenish S. Manzoor(AbbVie (United States)), Arliene Ravelo(Dana-Farber Cancer Institute), Gijs van de Wetering(Open University of the Netherlands), Sheila Shapouri(Dana-Farber Cancer Institute), Kavita Sail(AbbVie (United States))
Blood
November 13, 2019
10.1182/blood-2019-123706
Cited by 11

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k